Splash Beverage Acquires Exclusive Global Rights to CannEpil.
Splash Beverage Group entered a global licensing deal for the epilepsy drug CannEpil and received $1 million in funding. This acquisition targets patients with drug-resistant epilepsy and leverages existing international commercialization pathways for U.S. development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day